Published on
Last updated on
Acceptance of Foreign Clinical Trial Data
Enhanced Acceptance of Foreign Clinical Trial Data. On 08.10.2017, the CPC Central Committee and State Council published “Deepening the Reform of the Examination and Approval System and Encouraging the Innovation of Pharmaceutical and Medical Devices (Draft for Comment)”. According to this, NMPA plans to accept foreign clinical trial data if it complies with Chinese requirements.NMPA comments on the following aspects of clinical trial management:
- Speeding up the review and approval of market entry
- Promoting drug innovation and generic drug development
- Strengthening the lifecycle management of pharmaceutical and MD
- Improving technical support
- Strengthening organization and implementation
Connect with Cisema
With more than 20 years of experience and a team of over 100 specialists, Cisema helps global companies achieve compliance across Asia Pacific with confidence and accelerate market entry.
Stay Informed with Monthly News and Analysis
Stay informed with the latest regulatory changes, expert insights, and market opportunities across APAC, delivered straight to your inbox.
Related News
China Expands MRI Registration Requirements Under New 2026 Review Guideline
Manufacturers seeking MRI registration in China must meet expanded technical, software, and validation requirements.
China CMDE Releases New Review Documents for Oncology NGS & HLA-B*58:01 Reagents
The new documents clarify expectations for Tier III variants, companion diagnostic clinical evaluation, tissue and plasma registration, and HLA-B*58:01 analytical validation.
Taiwan Extends Cosmetic GMP Requirements to Nearly All Manufacturing Sites
As of July 1, 2026, Taiwan has completed its cosmetic GMP rollout, extending mandatory ISO 22716-based manufacturing standards to nearly all cosmetic factories